Floatz logo

Elezanumab

Acute Ischemic Stroke

AbbViemonoclonal_antibodyPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

211 Active assets in the Acute Ischemic Stroke cohort.

Asset / SponsorPhaseRating
Ticagrelor
Sichuan Provincial People's Hospital
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Compound Edaravone
Nanfang Hospital, Southern Medical University
Phase 4BBB
Tenecteplase
Hackensack Meridian Health
Phase 4BBB
Argatroban
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB

View all 50 →

Same molecule, other indications

Elezanumab is also rated in:

multiple sclerosisDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →